Which longevity data is worth acting on?
Diagnostics · Biomarkers

Which longevity data is worth acting on?

For years, we said we didn’t have enough data for precision medicine. Now we have more than we can interpret.

By David Luu, MDSep 27, 2026

The Brief

In brief, for a busy clinic day.

Get The Brief

The Sunday edition.

The week in longevity medicine, every Sunday.

Free, delivered by Substack. Unsubscribe any time.
Embed not loading? Subscribe on Substack

Research

New studies and what they mean for practice, read by physicians.

See all

Clinical Practice

How longevity medicine is delivered: practice models, cases and standards.

See all

Therapeutics

What physicians prescribe, and what the evidence supports.

See all

Diagnostics

Biomarkers, imaging and the tests entering the longevity visit.

See all

Technology

AI, wearables and the tools entering the exam room.

See all

Business

Companies, capital and care delivery shaping longevity medicine.

See all

Policy

Regulation, payment and the standards that govern longevity care.

See all

Voices

Opinion and perspective from physicians in the longevitydocs™ network.

See all